{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T13:18:48Z","timestamp":1747747128926},"reference-count":0,"publisher":"American Physiological Society","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American Journal of Physiology-Regulatory, Integrative and Comparative Physiology"],"published-print":{"date-parts":[[1996,9,1]]},"abstract":"<jats:p> To investigate whether expression of the renal angiotensinogen gene is regulated by dopaminergic receptors, we used opossum kidney (OK 27) cells with a fusion gene containing the 5'- flanking regulatory sequence of the rat angiotensinogen gene fused with a human growth hormone (hGH) gene as a reporter [pOGH, angiotensinogen nucleotide (N) -1498\/+18], permanently integrated into their genomes. The level of expression of pOGH (angiotensinogen N-1498\/+18) in OK 27 was evaluated by the amount of immunoreactive hGH (ir-hGH) secreted into the culture medium. In the absence of 3-isobutyl-1-methylxanthine (IBMX), addition of dopamine (10(-13) to 10(-5)M) had minimal effect on the expression of the pOGH (angiotensinogen N-1498\/+18) in OK 27 cells. In the presence of IBMX, addition of low concentrations (10(-13) and 10(-7) M) of dopamine stimulated the expression of pOGH angiotensinogen N-1498\/+18) in OK 27 cells in a dose-dependent manner, whereas high concentrations (i.e., &gt; 10(-7) M) had minimal effect. The stimulatory effect of dopamine on the expression of pOGH (angiotensinogen N-1498\/+18) was inhibited by the presence of SCH-23390 (D1-dopaminergic receptor antagonist) and spiperone (D2-dopaminergic receptor antagonist), but not by ketanserin (5 HT2\/5HT1c-serotonergic receptor antagonist). Moreover, the stimulatory effect of dopamine was inhibited by the presence of U-73122 (an inhibitor of phospholipase C and phospholipase A2) or staurosporine (an inhibitor of protein kinase C) or (R)-p-adenosine 3',5'-cyclic monophosphorothioate (Rp-cAMP[S]; an inhibitor of cAMP-dependent protein kinase AI and II). Addition of low concentrations (10(-13) to 10(-9)M) of SKF-82958 (D1-dopaminergic receptor agonist) or PPHT (D2-dopaminergic receptor agonist) also stimulated the expression of pOGH (angiotensinogen N-1498\/+18). The stimulatory effect of SKF-82958 was inhibited by the presence of SCH-23390 or Rp-cAMP[S], whereas the effect of PPHT was inhibited by the presence of spiperone or staurosporine. These studies demonstrate that the expression of pOGH (angiotensinogen N-1498\/+18) in OK 27 cells is modulated by dopaminergic receptor agonists. <\/jats:p>","DOI":"10.1152\/ajpregu.1996.271.3.r519","type":"journal-article","created":{"date-parts":[[2017,12,24]],"date-time":"2017-12-24T23:47:16Z","timestamp":1514159236000},"page":"R519-R527","source":"Crossref","is-referenced-by-count":2,"title":["Dopaminergic receptors and angiotensinogen gene expression in opossum kidney cells"],"prefix":"10.1152","volume":"271","author":[{"given":"T. T.","family":"Wang","sequence":"first","affiliation":[{"name":"University of Montreal, Maisonneuve-Rosemont Hospital, ResearchCenter, Quebec, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Lachance","sequence":"additional","affiliation":[{"name":"University of Montreal, Maisonneuve-Rosemont Hospital, ResearchCenter, Quebec, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Delalandre","sequence":"additional","affiliation":[{"name":"University of Montreal, Maisonneuve-Rosemont Hospital, ResearchCenter, Quebec, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Carriere","sequence":"additional","affiliation":[{"name":"University of Montreal, Maisonneuve-Rosemont Hospital, ResearchCenter, Quebec, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. S.","family":"Chan","sequence":"additional","affiliation":[{"name":"University of Montreal, Maisonneuve-Rosemont Hospital, ResearchCenter, Quebec, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"24","container-title":["American Journal of Physiology-Regulatory, Integrative and Comparative Physiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.physiology.org\/doi\/pdf\/10.1152\/ajpregu.1996.271.3.R519","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,9]],"date-time":"2019-09-09T03:24:41Z","timestamp":1567999481000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.physiology.org\/doi\/10.1152\/ajpregu.1996.271.3.R519"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1996,9,1]]},"references-count":0,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1996,9,1]]}},"alternative-id":["10.1152\/ajpregu.1996.271.3.R519"],"URL":"https:\/\/doi.org\/10.1152\/ajpregu.1996.271.3.r519","relation":{},"ISSN":["0363-6119","1522-1490"],"issn-type":[{"value":"0363-6119","type":"print"},{"value":"1522-1490","type":"electronic"}],"subject":[],"published":{"date-parts":[[1996,9,1]]}}}